Peptide Conjugates Market Share, Demand and Trends 2034
Global Peptide Drug Conjugates Market Growth, Size, Trends Analysis - By Product, By Type - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Sep-2025 | Report ID: PHAR2525 | Pages: 1 - 279 | Formats*: |
| Category : Pharmaceutical | |||
Global Peptide Drug Conjugates Market Introduction and Overview
According to SPER Market Research, the Global Peptide Drug Conjugates Market is estimated to reach USD 23.4 billion by 2034 with a CAGR of 19.47%.
The report includes an in-depth analysis of the Global Peptide Drug Conjugates Market, including market size and trends, product mix, Applications, and supplier analysis. The global peptide drug conjugates market was valued at USD 3.95 billion in 2024, and it is expected to rise at a 19.47% CAGR from 2025 to 2034. The market for peptide drug conjugates is driven by the growing need for targeted drug delivery systems. The use of peptide-based therapeutics is fueled by the rising incidence of chronic illnesses. The market is also expanding more quickly due to technological breakthroughs and rising R&D expenditures by pharmaceutical firms.
By Product Insights
The pluvicto segment dominated the market in 2024, and it is anticipated to grow at the quickest rate throughout the projected period. The market for peptide drug conjugates (PDCs) is significantly influenced by the success of Novartis' PSMA-targeted radioligand treatment, Pluvicto. Although Pluvicto is not a PDC in and of itself, its method of specifically targeting prostate cancer cells that express PSMA is in line with the increasing need for precision oncology treatments, such as peptide-based drug delivery systems. The need for highly specific, biomarker-driven treatments is highlighted by the growing use of targeted therapeutics like Pluvicto, opening the door for PDCs that conjugate cytotoxic medications to PSMA-targeting peptides.
By Type Insights
The therapeutic sector is expected to develop at the quickest rate and led the market in 2024. Due to the availability of approved PDCs like Lutathera and Pluvicto, the therapeutics segment is anticipated to increase significantly. PDCs such as Illuccix, BT5528, and others are being evaluated in a number of clinical trials as targeted therapeutics against malignant cells. Pharmaceutical firms are creating PDCs for ailments other than cancer, including as metabolic disorders, which is propelling the market's growth.
Regional Insights
North America's peptide drug conjugate market had the highest revenue share in 2024 due to increased use of targeted medicines, improvements in peptide synthesis technology, and the high incidence of cancer and chronic illnesses. Early regulatory approvals, large biopharmaceutical investments, and the expanding usage of RNA -based treatments are all advantageous to the area.
Market Competitive Landscape
The peptide drug conjugates market is moderately consolidated due to the presence of numerous domestic and foreign companies. The major companies including AstraZeneca, Novartis AG are actively engaged through strong pipelines and partnerships. These companies made strategic alliances, late stage trials.
Recent Developments:
In January 2025, Oncopeptides AB announced that the Italian Official Journal had published a favorable reimbursement decision for its drug Pepaxti (melflufen).
In May 2024, Oncopeptides AB announced that the first hospital in Spain began treating patients with Pepaxti, a critical milestone in the drug's commercial rollout.
In April 2024, Novartis AG invested USD 180 million in radioligand therapeutic development through their Peptide-Drug Conjugate (PDC) cooperation with PeptiDream. This investment demonstrates the growing emphasis on targeted peptide-based medicines in oncology and beyond.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By Type |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa |
| Companies Covered | Novartis AG, AstraZeneca, Oncopeptides AB, Bicycle Therapeutics, Cybrexa, Angiochem Inc, Soricimed Biopharma, Theratechnologies Inc. |
Key Topics Covered in the Report
- Global Peptide Drug Conjugates Market Size (FY’2021-FY’2034)
- Overview of Global Peptide Drug Conjugates Market
- Segmentation of Global Peptide Drug Conjugates Market By Product (OctreoScan, Lutathera, Pluvicto, Illuccix, Others)
- Segmentation of Global Peptide Drug Conjugates Market By Type (Therapeutic, Diagnostic)
- Statistical Snap of Global Peptide Drug Conjugates Market
- Expansion Analysis of Global Peptide Drug Conjugates Market
- Problems and Obstacles in Global Peptide Drug Conjugates Market
- Competitive Landscape in the Global Peptide Drug Conjugates Market
- Details on Current Investment in Global Peptide Drug Conjugates Market
- Competitive Analysis of Global Peptide Drug Conjugates Market
- Prominent Players in the Global Peptide Drug Conjugates Market
- SWOT Analysis of Global Peptide Drug Conjugates Market
- Global Peptide Drug Conjugates Market Future Outlook and Projections (FY’2025-FY’2034)
- Recommendations from Analyst
1.Introduction
1.1.Scope of the report1.2.Market segment analysis
2.Research Methodology
2.1.Research data source
2.1.1.Secondary Data2.1.2.Primary Data2.1.3.SPERs internal database2.1.4.Premium insight from KOLs
2.2.Market size estimation
2.2.1.Top-down and Bottom-up approach
2.3.Data triangulation
3.Executive Summary
4.Market Dynamics
4.1.Driver, Restraint, Opportunity and Challenges analysis
4.1.1.Drivers4.1.2.Restraints4.1.3.Opportunities4.1.4.Challenges
5.Market variable and outlook
5.1.SWOT Analysis
5.1.1.Strengths5.1.2.Weaknesses5.1.3.Opportunities5.1.4.Threats
5.2.PESTEL Analysis
5.2.1.Political Landscape5.2.2.Economic Landscape5.2.3.Social Landscape5.2.4.Technological Landscape5.2.5.Environmental Landscape5.2.6.Legal Landscape
5.3.PORTERs Five Forces
5.3.1.Bargaining power of suppliers5.3.2.Bargaining power of buyers5.3.3.Threat of Substitute5.3.4.Threat of new entrant5.3.5.Competitive rivalry
5.4.Heat Map Analysis
6.Competitive Landscape
6.1.Global Peptide Drug Conjugates Market Manufacturing Base Distribution, Sales Area, Product Type6.2.Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Peptide Drug Conjugates Market
7.Global Peptide Drug Conjugates Market, By Product (USD Million) 2021-2034
7.1.OctreoScan7.2.Lutathera7.3.Pluvicto7.4.Illuccix7.5.Others
8.Global Peptide Drug Conjugates Market, By Type (USD Million) 2021-2034
8.1.Therapeutic8.2.Diagnostic
9.Global Peptide Drug Conjugates Market, (USD Million) 2021-2034
9.1.Global Peptide Drug Conjugates Market Size and Market Share
10.Global Peptide Drug Conjugates Market, By Region, (USD Million) 2021-2034
10.1.Asia-Pacific
10.1.1.Australia10.1.2.China10.1.3.India10.1.4.Japan10.1.5.South Korea10.1.6.Rest of Asia-Pacific
10.2.Europe
10.2.1.France10.2.2.Germany10.2.3.Italy10.2.4.Spain10.2.5.United Kingdom10.2.6.Rest of Europe
10.3.Middle East and Africa
10.3.1.Kingdom of Saudi Arabia10.3.2.United Arab Emirates10.3.3.Qatar10.3.4.South Africa10.3.5.Egypt10.3.6.Morocco10.3.7.Nigeria10.3.8.Rest of Middle-East and Africa
10.4.North America
10.4.1.Canada10.4.2.Mexico10.4.3.United States
10.5.Latin America
10.5.1.Argentina10.5.2.Brazil10.5.3.Rest of Latin America
11.Company Profile
11.1.Novartis AG
11.1.1.Company details11.1.2.Financial outlook11.1.3.Product summary11.1.4.Recent developments
11.2.AstraZeneca
11.2.1.Company details11.2.2.Financial outlook11.2.3.Product summary11.2.4.Recent developments
11.3.Oncopeptides AB
11.3.1.Company details11.3.2.Financial outlook11.3.3.Product summary11.3.4.Recent developments
11.4.Bicycle Therapeutics
11.4.1.Company details11.4.2.Financial outlook11.4.3.Product summary11.4.4.Recent developments
11.5.Cybrexa
11.5.1.Company details11.5.2.Financial outlook11.5.3.Product summary11.5.4.Recent developments
11.6.Angiochem Inc.
11.6.1.Company details11.6.2.Financial outlook11.6.3.Product summary11.6.4.Recent developments
11.7.Soricimed Biopharma
11.7.1.Company details11.7.2.Financial outlook11.7.3.Product summary11.7.4.Recent developments
11.8.Theratechnologies Inc
11.8.1.Company details11.8.2.Financial outlook11.8.3.Product summary11.8.4.Recent developments
11.9.Others
12.Conclusion
13.List of Abbreviations
14.Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Peptide Conjugates Market CAGR of 19.47% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Peptide Conjugates Market size is USD 23.4 billion from 2025 to 2034.
Peptide Conjugates Market covered By Product, By Type
The North America is anticipated to have the highest Market share in the Peptide Conjugates Market.
Novartis AG, AstraZeneca, Oncopeptides AB, Bicycle Therapeutics, Cybrexa, Angiochem Inc, Soricimed Biopharma, Theratechnologies Inc.
The report includes an in-depth analysis of the Global Peptide Drug Conjugates Market, including market size and trends, product mix, Applications, and supplier analysis.
Peptide Conjugates Market is projected to reach USD 23.4 billion by 2034, growing at a CAGR of 19.47% during the forecast period.
Peptide Conjugates Market size from 2025. The Market is expected to reach USD 23.4 billion by 2034, at a CAGR of 19.47% during the forecast period.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
